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Abstract
Clinical observations have demonstrated that excessive 
chronic alcohol use negatively affects human immuno-
deficiency virus (HIV) infection and contributes to the 
liver manifestations of the disease, even in HIV mono-
infection. HIV/hepatitis C virus (HCV) co-infection is as-
sociated with increased progression of HVC liver disease 
compared to HCV infection alone, and both of these are 
negatively affected by alcohol use. Recent data suggest 
that alcohol use and HIV infection have common targets 
that contribute to progression of liver disease. Both HIV 
infection and chronic alcohol use are associated with in-
creased gut permeability and elevated plasma levels of 
lipopolysaccharide; a central activator of inflammatory 
responses. Both alcoholic liver disease and HIV infec-
tion result in non-specific activation of innate immunity, 
proinflammatory cytokine cascade upregulation, as well 
as impaired antigen presenting cell and dendritic cell 
functions. Finally, alcohol, HIV and antiretroviral therapy 
affect hepatocyte functions, which contributes to liver 
damage. The common targets of alcohol and HIV infec-
tion in liver disease are discussed in this mini-review.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
The life expectancy of  patients infected with human im-
munodeficiency virus (HIV) has been prolonged, there-
fore, liver diseases have assumed far greater importance 
as a cause of  morbidity and mortality in these patients. 
Antiretroviral therapy (ART) used by patients who have 
HIV infection is often hepatotoxic. In addition, patients 
who have HIV often are co-infected with hepatotropic 
viruses such as hepatitis B and C viruses; factors that are 
damaging to the liver. Furthermore, chronic alcohol con-
sumption causes injury to the liver and may result in more 
rapid progression to cirrhosis, end-stage liver disease, and 
hepatocellular carcinoma in co-infected patients. This re-
view addresses the interactions between these factors that 
result in furthering liver damage.
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HIV, VIRAL HEPATITIS AND ALCOHOL 
USE - EPIDEMIOLOGY AND NATURAL 
HISTORY OF LIVER DISEASE
The natural history of  HIV infection has drastically 
changed since the discovery of  its clinical manifestation, 
AIDS in advanced disease[1-3]. HIV affects about 40 million 
people worldwide, with most of  the infections in develop-
ing countries. As a blood-borne pathogen, HIV infection 
is transmitted via blood, sexual contact, and maternal-
newborn transfer. HIV primarily infects immune cells and 
it replicates in T lymphocytes and monocytes[4-7]. HIV 
mono-infection results in minimal hepatitis, however, co-
infection with hepatitis virus results in increased liver dam-
age. Hepatitis B virus (HBV) infection affects 370 million 
people and it is estimated that an additional 170 million 
suffer from hepatitis C virus (HCV) infection[8-13]. Both 
HBV and HCV can lead to chronic hepatitis and as a result, 
progressive liver inflammation and fibrosis lead to cirrhosis 
and liver failure. An additional insult to the liver is excessive 
alcohol consumption that is an ongoing social and medical 
problem in people with and without HIV infection. 
Several studies have found significant alcohol problems 
in HIV-infected individuals. In a primary care setting, physi-
cians have reported that alcohol consumption is a common 
habit in patients initiating care for HIV disease[14-16]. Heavy 
drinking among people with HIV infection under medical 
care has been found to be almost double that of  the general 
population[17]. It has also been shown that heavy alcohol 
consumption has a negative impact on CD4 cell count in 
HIV-infected persons who are not receiving ART[18].
The interaction of  HIV and HCV infection has re-
ceived increasing attention in recent years. It has been well 
documented that liver disease progression is accelerated in 
HIV/HCV co-infected patients compared with HIV or 
even HCV mono-infection[11,13,19]. Furthermore, chronic 
heavy alcohol consumption acts as an additional insult in all 
of  these forms of  chronic hepatitis. With the new era of  
highly active antiretroviral therapy (HAART) that provides 
sufficient control of  HIV replication, it has become evi-
dent that, in HIV/HCV co-infected patients, progression 
of  HCV infection causes more lethality than HIV infec-
tion itself[11,13,19]. 
Excessive alcohol consumption is associated with fatty 
liver, and if  persistent, it can lead to alcoholic steatohepa-
titis, liver fibrosis and cirrhosis[20]. Clinical studies have 
demonstrated that excessive alcohol consumption in indi-
viduals with comorbid conditions such as chronic HCV or 
HBV infection accelerates liver damage and progression to 
liver cirrhosis. In a study of  a large cohort of  HIV-positive 
and negative US veterans, investigators have found a trend 
toward increased liver injury manifested as inflammation 
and fibrosis, in patients with hazardous or binge drink-
ing[21]. The same study has shown that alcohol abuse and 
dependence significantly increase the risk of  advanced 
fibrosis and cirrhosis in HIV-mono-infected patients, as 
well as in those with HIV/HCV co-infection[21]. A cross-
sectional study has investigated the impact of  alcohol on 
liver fibrosis using aspartate aminotransferase (AST)-to-
platelet ratio index (APRI) as a measure of  liver function, 
and has found significant liver disease with an APRI > 1.5. 
This study also has found that hazardous alcohol drinking 
is an independent, modifiable risk factor for fibrosis[21], and 
the same investigators have concluded that the problem of  
alcohol abuse is not adequately addressed by health care 
providers in patients with HIV positivity[21].
In HIV-infected patients, 17% of  death was related 
to end-stage liver disease; of  those, 75% of  patients had 
HIV/HCV co-infection and 48% heavy alcohol use his-
tory[22]. Alcohol use in HIV-infected patients was also 
shown to be associated with decreased adherence to ART, 
and not surprisingly, reduced HIV suppression[23].
ALCOHOL AND HIV: COMMON TARGETS 
IN LIVER DISEASE
Although the pathological mechanisms of  alcoholic liver 
disease are relatively well explored[24-26], the mechanisms 
by which HIV infection affects the liver remain somewhat 
elusive. Based on current knowledge, several elements in 
the pathological mechanisms of  alcohol-induced liver dis-
ease can by exacerbated by HIV infection, which results in 
the potentiation of  the individual negative effects. These 
major categories of  mutual actions and modulating effects 
of  both alcohol and HIV infection are on gut perme-
ability and gut-liver homeostasis, immune functions and 
inflammation, and alterations in hepatocyte functions and 
survival (Figure 1).
Gut permeability and the role of lipopolysaccharide in 
HIV infection and alcoholic liver disease
The important role of  gut-derived lipopolysaccharide 
(LPS) has been demonstrated in alcoholic liver disease in 
humans, as well as in animal models of  chronic alcohol 
administration[27,28]. Gut-derived LPS has been shown to 
have a causative role in alcoholic liver injury as demon-
strated by experiments in which gut sterilization with an-
tibiotics prevented alcohol-induced liver damage[29]. This 
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Figure 1  Alcohol and human immunodeficiency virus in liver disease. 
There are multiple common sites of action of alcohol and human immunodefi-
ciency virus (HIV) infection that contribute to the development of liver disease. 
These include modification of immune functions and inflammatory responses, 
functions of hepatocytes and intestinal permeability.
was associated with increased intestinal permeability in 
rats[30]. Alcohol feeding in rats and mice increases serum 
endotoxin levels after 1-2 wk, and these increases remain 
after continued alcohol administration[31]. Studies in mice 
as well as in vitro have demonstrated that alcohol damages 
the intestinal epithelial barrier by downregulating tight 
junction proteins[32-34]. The importance of  the gut-liver 
axis has been implicated in alcoholic liver diseases and in 
other etiologies of  liver injury[27,28].
The novel finding, that HIV infection is associated 
with increased plasma endotoxin levels was first reported 
by Douek’s group in 2006[35]. Plasma LPS was significantly 
increased in patients with chronic HIV infection, as well as 
in patients with AIDS compared to uninfected controls or 
to those with acute infection[35]. LPS in the serum is bound 
to lipoprotein binding protein (LBP) and soluble CD14 
(sCD14) that modulate the biological availability of  LPS. 
The same authors have found increased plasma sCD14 
and LBP levels even in acute HIV infection, as well as in 
those with progressive HIV infection[35]. Subsequent stud-
ies have evaluated the effect of  ART on plasma LPS levels 
and have found that patients with ART have a moderate 
decrease in plasma LPS levels[36]. This is also associated 
with an improvement in plasma tumor necrosis factor 
(TNF)α levels, which suggests attenuation of  inflammato-
ry cell activation[36-38]. The source of  the increased plasma 
LPS in HIV infection is presumably the gut. It has been 
speculated that HIV infection in the intestinal epithelial 
and immune environment permits increased translocation 
of  gut microbiota and their components such as LPS[39].
Increased serum LPS levels have been noted in pa-
tients with chronic HCV infection, even in the absence 
of  advanced liver disease[40]. Furthermore, in patients with 
HCV and HIV co-infection, serum LPS levels are higher 
compared to those in patients with HIV infection alone[41]. 
The biological significance of  the elevated serum or 
plasma LPS in HIV infection is yet to be fully understood. 
It is generally accepted that chronic LPS exposure of  
immune and inflammatory cells results in a non-specific 
inflammation that may “reset” thresholds for specific im-
mune responses[42]. It is tempting to speculate that constant 
and repeated exposure of  innate immune cells, particularly 
tissue macrophages (Kupffer cells) in the liver from the 
gut-derived LPS in the portal blood, could result in loss of  
LPS tolerance, which predisposes to increased inflamma-
tory responses[43]. We have found loss of  Toll-like receptor 
(TLR) tolerance in circulating monocytes of  HCV-infected 
patients, and this is associated with increased production 
of  proinflammatory signals including TNFα[40]. 
In alcoholic liver disease, there is a large body of  
evidence in support of  increased sensitivity of  Kupffer 
cells to LPS and proinflammatory cytokine activation[44,45] 
(Figure 2). Early studies have demonstrated that elimina-
tion of  Kupffer cells with gadolinium chloride in rats 
ameliorates alcohol-induced liver damage and that LPS/
CD14 receptor signaling is involved[44]. Recently, we have 
shown that deficiency in TLR4, the receptor for LPS, or 
deficiency in the TLR4 downstream signaling by inter-
feron regulatory factor 3, are crucial for development of  
alcohol-induced liver damage[31,46]. The combined effect 
of  alcohol and HIV infection on LPS signaling in the liver 
awaits further investigation.
Inflammation and immune functions
Activation of  the inflammatory cascade and increased pro-
inflammatory cytokine production is a hallmark of  both 
alcoholic steatohepatitis and chronic HIV infection[26,45]. 
The immunological consequences of  such proinflamma-
tory cascade activation are not fully understood. The clini-
cal observations of  increased susceptibility to infections 
in alcoholic steatohepatitis and chronic HIV infection 
demonstrate that, although non-specific proinflammatory 
activation is present, pathogen-specific innate immune 
responses are defective. Furthermore, antigen-specific im-
mune responses as well as antigen presenting function of  
monocytes and dendritic cells are severely dampened by 
alcohol exposure, as well as in chronic HIV infection[47-49]. 
Our previous studies have demonstrated that acute alcohol 
consumption in humans inhibits the antigen presenting 
function in human monocyte-derived dendritic cells and 
monocytes via mechanisms that involve decreased interleu-
kin (IL)-12 and co-stimulatory molecule expression and/or 
impaired dendritic cell differentiation/maturation[48-50]. The 
effects of  prolonged alcohol also inhibit myeloid dendritic 
cell functions in humans as well as mouse models[51]. 
Defects in myeloid and plasmacytoid dendritic cell 
function have been extensively studied in HIV infection. It 
has been shown that HIV infection results in impaired dif-
ferentiation and maturation of  monocyte-derived dendritic 
cells in humans and that these dendritic cells have impaired 
antigen presentation capacity. Chronic HCV infection is 
also associated with decreased antigen presenting function 
of  dendritic cells and HIV and HCV infection affect im-
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Figure 2  Alcohol-induced hepatocyte damage is amplified by human im-
munodeficiency virus infection. The current model of alcohol-induced liver dis-
ease includes increased gut-derived lipopolysaccharide (LPS) entry into the liver 
where Kupffer cells are activated via LPS/Toll-like receptor (TLR) 4 and produce 
tumor necrosis factor (TNF)α. Human immunodeficiency virus (HIV) infection also 
increases gut-derived LPS levels in the circulating blood. Increased production of 
TNFα will act on alcohol-exposed hepatocytes to induce apoptosis. ROS: Reac-
tive oxygen species.
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mune responses[52,53]. Although the combined effects of  
alcohol exposure and HIV infection are yet to be evaluated 
on dendritic cell functions, we have previously demonstrat-
ed that alcohol treatment has an additive inhibitory effect 
on the already dampened accessory cell function in den-
dritic cells of  HCV-infected patients[54]. This is associated 
with reduced expression of  the T cell co-stimulatory mol-
ecules, CD80 and CD86, low IL-12 and increased IL-10 
production[54]. The role of  dendritic cells in HIV/HCV 
co-infection in relation to the liver disease needs further 
exploration. However, the importance of  dendritic cells in 
liver tolerance and inflammation is emerging[42,43].
Hepatocyte function and cell death
There are multiple mechanisms by which alcohol, HIV 
infection and even ART could directly affect hepatocytes. 
As summarized in Table 1, reactive oxygen radical pro-
duction, mitochondrial damage and steatosis can all be 
induced independently by alcohol, HIV or HCV infec-
tions alone or in combination with HAART[55]. However, 
these factors together will most likely cause combined 
damage in exposed hepatocytes. Some of  the mechanisms 
involved include depletion of  the intracellular glutathione 
stores by chronic alcohol and HIV infection that predis-
poses to increased reactive oxygen species (ROS) produc-
tion and increased susceptibility to hepatocyte death[55]. In 
addition, alcohol, HCV, and HAART cause mitochondrial 
damage, fatty liver, and increased levels of  proinflam-
matory cytokines, particularly, TNFα, which results in 
hepatocyte death. This mechanism has been investigated 
in alcoholic liver damage as well as in HIV infection, and 
HIV/HCV co-infection[55].
Although the introduction of  HAART for HIV infec-
tion has resulted in a significant decrease in the mortality 
rate of  AIDS, a sizable proportion of  patients receiving 
HAART develop liver toxicity. For example, patients treat-
ed with the antiretroviral nucleoside reverse-transcriptase 
inhibitors (NRTIs) zidovudine, zalcitabine, didanosine 
and stavudine have been reported to develop hepatic ste-
atosis[56,57]. Heavy alcohol consumption by HIV patients 
on HAART results in liver decompensation in about 2% 
of  cases[58], and increases the risk of  liver injury 5.8 times 
in 10% of  patients receiving NRTI or non-NRTI regi-
mens[55]. The enhanced liver toxicity due to alcohol, HCV, 
and HAART could result from shared mechanisms such 
as fat accumulation and mitochondrial damage.
Fat accumulation and insulin resistance
Alcohol and HCV-induced fatty liver is well documented. 
Several mechanisms have been reported for alcohol-
induced fatty liver including increased hepatic uptake of  
fatty acids and de novo lipogenesis, impaired peroxisome 
proliferator-activated receptor α signaling, reduced mi-
tochondrial fatty acid oxidation and reduced secretion 
of  triglycerides[59-61]. These effects could be attributed to 
reduced adiponectin secretion by the adipose tissue and 
elevated expression of  TNFα[62-64].
Some AIDS patients develop HAART-associated lipo-
dystrophy (LD). A study by Sutinen et al[65] has shown that, 
in comparison to HIV-negative subjects, HAART+LD 
patients show: (1) higher liver fat content (regardless of  
alcohol consumption); (2) for a given amount of  liver fat, 
serum-free insulin concentration correlated with liver fat, 
which suggests that fat accumulation in the liver is crucial 
for development of  insulin resistance; and (3) significantly 
lower leptin concentrations than the other two groups. 
Others have also demonstrated low plasma leptin concen-
trations in patients with HAART-associated LD[66]. Hypo-
leptinemia and subsequent insulin resistance could favor 
fatty liver accumulation in patients suffering from NRTI-
induced lipoatrophy[67-69].
Although Sutinen and co-workers did not observe 
lactic acidosis, others have reported lactic acidosis and he-
patic steatosis in some patients using HAART, which was 
attributed to mitochondrial toxicity induced by nucleoside 
analogs[70,71]. In addition, co-infection with HCV increases 
the risk for severe liver damage during HAART[72], and 
end-stage liver disease is the primary cause of  death in 
HIV/HCV co-infected patients under HAART[73,74]. Seth[75] 
has reported that, in HIV co-infected patients, the HCV 
load is higher by an average of  0.5-1.0 log than the mono-
infected patients due to immune depression. Studies 
on liver fibrosis show conflicting results. Although some 
studies have found that early HAART in HIV/HCV co-
infected patients may slow liver fibrosis progression[76], 
others have found that HAART regimens including nevi-
rapine accelerate liver fibrosis progression in HIV/HCV 
co-infected patients[77]. 
Mitochondrial damage
Alcohol and HCV can induce mitochondrial DNA (mtD-
NA) damage through the production of  ROS and/or re-
active metabolites. It has been reported that prolonged ad-
ministration of  antiretroviral NRTIs increases the risk of  
mitochondrial damage in the liver[78]. NRTIs can cause the 
accumulation of  the oxidized base 8-hydroxydeoxyguano-
sine (8-OH-dG) in liver mtDNA[79,80]. In addition, NRTIs 
can cause mtDNA point mutations in some patients, which 
may result from interaction with mtDNA replication (via 
misreading of  8-OH-dG by DNA polymerase c) and/or 
impairment of  polymerase c repair capacity[81]. It has 
been reported that NRTIs inhibit mtDNA replication by 
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Table 1  Common mechanisms of liver/hepatocyte damage
Effect HIV HCV Alcohol HAART
Increase ROS √ √ √
Increase proinflammatory cytokines √ √ √
Oxidative stress √ √ √ √
Lipid peroxidation √ √ √
Mitochondrial damage √ √ √ √
Steatosis √ √ √ √
Glutathione depletion √ √ √
Proteasome dysfunction √ √
HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; HAART: 
Highly active antiretroviral therapy; ROS: Reactive oxygen species.
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undergoing phosphorylation as the cognate endogenous 
nucleosides, which are subsequently incorporated within 
the mitochondrial genome by DNA polymerase c[81].
CONCLUSION
Although increasing evidence suggests enhanced com-
bined effects of  alcohol and HIV infection on the liver 
with and without viral hepatitis, a number of  questions re-
main unanswered. What are the interactions between alco-
hol use, HIV, HCV and HBV infections? Is the crosstalk 
between organs, such as the homeostasis between the liver 
and gut, affected by combined insults of  alcohol, HIV and 
viral hepatitis? What is the effect of  the cumulative effects 
of  alcohol and HIV infection on cross-regulation between 
various cell types in the liver? How can new therapeutic 
targets be developed in the light of  knowledge about the 
interactive effects of  HIV and alcohol on the liver? All of  
these questions are pertinent to the status and defects ob-
served in immune functions, gut permeability, Kupffer cell 
activation, hepatocyte function and liver fibrosis/stellate 
cell function in patients with HIV infection and excessive 
alcohol use and/or viral hepatitis.
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